Effects of dexamethasone, all-trans retinoic acid, vitamin D3 and interferon-α on FO myeloma cells

Chemotherapy

Volumn 50, Issue 4, 2004, Pages 190-193

  Ozdemir, Feyyaz ^a   Esen, Nilgun ^a   Ovali, Ercument ^a   Tekelioglu, Yavuz ^a   Yilmaz, Mustafa ^a   Aydin, Fazil ^a   Kavgaci, Halil ^a   Boruban, Cem ^b  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

All trans retinoic acid; Dexamethasone; FO myeloma cells; Interferon ; Vitamin D3

Indexed keywords

ALPHA INTERFERON; COLECALCIFEROL; DEXAMETHASONE; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID; VESENOID;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL COUNT; CHOLECALCIFEROL; DEXAMETHASONE; DRUG INTERACTIONS; INTERFERON-ALPHA; MICE; MULTIPLE MYELOMA; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 8344283471     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080693     Document Type: Article

References (24)

1. Foerster J: Multiple myeloma; in Lee GR, Bithell TC, Forster J, Ethens J, Lukens JN (eds): Wintrobe's Clinical Haematology. London, Lee Farber,1993, pp 2219-2249.
2. Durie BGM, Giles FJ: Myeloma and other paraproteinemias; in Weatherall DJ, Ledingham JGG, Warrell DA (eds): Oxford Textbook of Medicine. New York, Oxford University Press, ed 3,1996, pp 3597-3605.
3. Longo DL: Plasma cell disorders; in Issebacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds): Harrison's Principles of Internal Medicine. New York, McGraw-Hill, ed 13,1994, pp 1618-1625.
4. Ogata A, Nishimoto N, Shima Y, et al: Inhibitory effect of all-trans retinoic acid in the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994;84:3040-3046.
5. Urashima M, Teoh G, Chauhand, et al: Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells. Blood 1997;90:279-289.
6. Lu ZY, Zhang XG, Rodriguez C, et al: Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995;85:2521-2527.
7. Taetle R, Santos BD, Alamatsu KI, et al: Effect of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells. Clin Cancer Res 1996;2:253-259.
8. Jelinek DF, Aagaard-Tillery KM, Arendt BK, et al: Differential human multiple myeloma cell line responsiveness to interferon-α. Analysis of transcription factor activation and interleukin-6 receptor expression. J Clin Invest 1997;99:447-456.
9. INK4d and cyclin D2 expression. J Biol Chem 1998;273:11799-11805.
10. Salmon SE, Crowly JJ, Grogan TM, et al: Glucocorticoids and interferon-alfa in the treatment of multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1994;12:2405-2414.
11. Grander D, Xu B, Enhorn S: Cytotoxic effect of interferon on primary malignant tumor cells: Studies in various malignancies. Eur J Cancer 1993;29A:1940-1943.
12. Lawson-Matthew P, Clayton J, Guilland-Cumming D et al: Vit D metabolism in myeloma. Br J Haematol 1989;73:57-60.
13. Miller SA, Dykes DD, Polesky HF: A Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988;16:1215.
14. Aydin F, Ozdemir F, Kavgaci H et al: The effects of medroxyprogesterone acetate on apoptosis of CD34+ cells. Chemotherapy 2003;49:66-70.
15. Smith MR, Xie T, Joshi I, Schilder RJ: Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Br Haematol 1998;4:1090-1097.
16. Liu P, Oken M, Van Ness B: Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia 1999;3:473-480.
17. Lefebvre O, Wouters D, Mereau-Richard C, et al: Induction of apoptosis by all-trans retinoic acid in the human myeloma cell line RPMI 8226 and negative regulation of some of its typical morphological features by dexamethasone. Cell Death Differ 1999;5:433-444.
18. Bazarbashi S, Rahal M, Raja MA, et al: A pilot trial of combination cisplatin, 5-fluorouracil and interferon-A in the treatment of advanced esophageal carcinoma. Chemotherapy 2002;48:211-216.
19. 3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000;3:576-583.
20. Tassone P, Galea E, Forciniti S, et al: The IL-6 receptor super- antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. J Oncol 2002;21:867-873.
21. Otsuki T, Yata K, Sakaguchi H, et al: Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells. Br J Haematol 2002;116:787-795.
22. Song L, Li Y, Sun Y, et al: Study on the biological activity and molecular mechanism of IFN alpha on human myeloma cell line Sko-007. Zhonghua Xue Ye Xue Za Zhi 2002;23:517-519.
23. Song L, Li Y, Shen B: Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFN alpha. Cancer Cell Int 2002;2:8.
24. 3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Cancer Res 1988;48:1213-1216.